Equity work is often framed as something separate from “the business side” of healthcare. Dr. Manley argues it’s exactly the opposite. In this program, he lays out how inequities in lung cancer screening, biomarker testing, diagnosis, treatment, and clinical trials aren’t just moral failure - they are missed revenue, wasted resources, and long-term risk for health systems, payers, and life science companies.
Drawing on his experience in translational oncology, biomarkers, genomics, and his leadership at the SCHEQ Foundation, he explains how better outreach, earlier detection, plain-language education, and community-rooted partnerships can improve outcomes while also supporting sustainable growth. He speaks the language of clinicians, administrators, and industry, making the case that equity-focused strategies can reduce avoidable costs, strengthen reputation, and open new opportunities for innovation and partnerships.
This program is a strong fit for health system leadership retreats, payer strategy meetings, pharma and biotech teams, and foundations evaluating where to invest for maximum impact.
